Cargando…
1769. The Impact of Checkpoint Inhibitor Immunotherapy on Infections in Lung Cancer Patients
BACKGROUND: Immune checkpoint inhibitors (ICI) therapy has ushered cancer treatment into a potentially curative era. However, infectious complications remain largely unknown and the few studies that described infectious complications associated with ICI had no comparative control groups. We assessed...
Autores principales: | Malek, Alexandre, Fares, Johny, Khalil, Melissa, Hachem, Ray Y, Chaftari, Anne-Marie, Jiang, Ying, Kontoyiannis, Dimitrios P, Fossella, Frank, Chaftari, Patrick, Mulanovich, Victor E, Viola, George, Raad, Issam I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809399/ http://dx.doi.org/10.1093/ofid/ofz360.1632 |
Ejemplares similares
-
1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021) -
1636. Risk of Latent Tuberculosis Reactivation in Patients Treated with Checkpoint Inhibitors Immunotherapy Compared to Other Anti-Cancer Therapies including Hematopoietic Cell Transplantation
por: Malek, Alexandre, et al.
Publicado: (2020) -
1171. Impact of Catheter Management on the Clinical Outcome in Adult Cancer Patients with Gram-Negative Bacteremia
por: Fares, Johny, et al.
Publicado: (2019) -
Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients With Gram-Negative Bacteremia
por: Fares, Johny, et al.
Publicado: (2019) -
Procalcitonin for antimicrobial stewardship among cancer patients admitted with COVID-19
por: Dagher, Hiba, et al.
Publicado: (2022)